NCT00933270已完成不适用
Comparison of the SUpera® PERipheral System to a Performance Goal Derived From Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 325
- 试验地点
- 96
- 主要终点
- Primary Efficacy Endpoint: SFA Patency at 12 Months (± 30 Days), Defined as Freedom From Restenosis (PSVR ≥ 2.0) and TLR.
研究概览
简要总结
This is a prospective, multicenter, non-randomized, single arm, pivotal trial.
The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA® Nitinol Stent System in treating subjects with obstructive superficial femoral artery (SFA) disease. The primary endpoint will be the primary patency of the SFA evaluated at 12 months. The outcome will be compared to a performance goal based on clinical trials of percutaneous transvenous angioplasty (PTA) alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years and of age of legal consent.
- •Women of child bearing potential must have a negative pregnancy test within 7 days prior to the index procedure.
- •Subject has lifestyle limiting claudication or rest pain (Rutherford-Becker scale 2-4) with a resting ankle-brachial index (ABI) less than or equal to 0.
- •TBI (toe-brachial index) is performed only unable to assess ABI. TBI must be less than or equal to 0.
- •A single superficial femoral artery lesion with greater than 60% stenosis or total occlusion.
- •Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) greater than or equal to 40 mm to less than or equal to 140 mm. Reference vessel diameter (RVD) greater than or equal to 4.0 mm and less than or equal to 6.0 mm by visual assessment.
- •All lesions are to be located with the distal point at least 3 cm above the knee joint, defined as the distal end of the femur at the knee joint, and proximal point at least 2 cm below the origin of the profunda artery.
- •Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (less than 50% stenosis) to the ankle or foot.
- •The target lesion(s) can be successfully crossed with a guide wire and dilated.
- •Poor aortoiliac or common femoral "inflow" (i.e., angiographically defined greater than 50% stenosis of the iliac or common femoral artery) that would be deemed inadequate to support a femoropopliteal bypass graft must be successfully treated prior to treatment of the target lesion. This can be done just prior to treatment of the target lesion. Successful treatment is defined as less than 30% stenosis after either PTA or stenting of the inflow lesion. After treatment of the inflow lesion, the pressure gradient across the target lesion will be obtained and if the pressure gradient is greater than or equal to 20 mmHg, then the subject will be included in the study.
- •A subject with bilateral obstructive SFA disease is eligible for enrollment into the study. If a subject with bilateral disease is enrolled, the target limb will be selected at the Investigator's discretion, who may use the criteria of lesion length, percent stenosis, and/or calcification content. The contra-lateral procedure should not be done until at least 30 days after the index procedure (staged); however, if contralateral treatment is performed prior to treatment of the target lesion, the waiting period will be at least 14 days prior to the index procedure.
- •The subject is eligible for standard surgical repair, if necessary.
- •A subject who requires a coronary intervention should have it performed at least 7 days prior to the treatment of the target lesion.
- •Subject must provide written informed consent.
- •Subject must be willing to comply with the specified follow-up evaluation schedule.
排除标准
- •Thrombophlebitis or deep venous thrombus, within the previous 30 days.
- •Receiving dialysis or immunosuppressant therapy within the previous 30 days.
- •Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
- •Stroke within the previous 90 days.
- •Ipsilateral femoral aneurysm or aneurysm in the SFA or popliteal artery.
- •Required stent placement via a popliteal approach.
- •Required stent placement across or within 0.5 cm of the SFA/PFA bifurcation.
- •Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as in-stent restenosis.
- •Significant vessel tortuosity or other parameters prohibiting access to the lesion or 90° tortuosity which would prevent delivery of the stent device.
- •Required stent placement within 1 cm of a previously deployed stent.
- •Subject required a coronary intervention, and the coronary intervention was done less than 7 days prior to or planned within 30 days after the treatment of the target lesion.
- •Known allergies to any of the following: aspirin and all three of the following: clopidogrel bisulfate (Plavix®), ticlopidine (Ticlid®), and prasugrel (Effient®); heparin, nitinol (nickel titanium), or contrast agent, that cannot be medically managed.
- •Presence of thrombus prior to crossing the lesion.
- •Known or suspected active infection at the time of the procedure.
- •Presence of an ipsilateral arterial artificial graft.
- •Use of cryoplasty, laser, or atherectomy devices at the time of index procedure.
- •Restenotic lesion that had previously been treated by atherectomy, laser or cryoplasty within 3 months of the index procedure.
- •Subject has tissue loss, defined as Rutherford-Becker classification category 5 or
- •History of neutropenia, coagulopathy, or thrombocytopenia that was unexplained or is considered to be at risk for reoccurrence.
- •Known bleeding or hypercoagulability disorder or significant anemia (Hb < 8.0) that cannot be corrected.
- •Subject has the following laboratory values:
- •platelet count less than 80,000/μL,
- •international normalized ratio (INR) greater than 1.5,
- •serum creatinine level greater than 2.0 mg/dL.
- •Subject requires general anesthesia for the procedure.
- •Subject is pregnant or plans to become pregnant during the study.
- •Subject has a co-morbid illness that may result in a life expectancy of less than 1 year.
- •Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now FDA-approved product are not excluded by this criterion.
结局指标
主要结局
Primary Efficacy Endpoint: SFA Patency at 12 Months (± 30 Days), Defined as Freedom From Restenosis (PSVR ≥ 2.0) and TLR.
时间窗: 12 months
Patency of the target lesion was defined as no evidence of restenosis or occlusion within the originally treated lesion based on a centrally-read Color Flow Doppler ultrasound in the absence of target lesion revascularization (TLR). Occlusion and restenosis were defined as no color flow or an increase in peak systolic velocity of \> 2.0 when compared to the proximal normal segment.
Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days.
时间窗: 30 days
次要结局
- Long-Term Safety Endpoint (Clinically Driven TLR, Index Limb Amputation)(36 months (± 30 Days))
- Technical (Lesion) Success(intraoperative)
- Device Success(intraoperative)
- Secondary Safety Endpoint(36 months (± 30 Days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Treatment Satisfaction(12 months (± 30 Days))
- Procedural Success(intraoperative)
- Ankle-brachial Index (ABI) Measurements on Target Limb(1 month (± 7 Days))
- Major Adverse Events (MAVE)(36 months (±30 days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Symptom Stability(12 months (± 30 Days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Social Limitation(12 months (± 30 Days))
- Secondary Safety Composite Endpoint(12 months (± 30 Days))
- Target Lesion Revascularization (TLR)(36 months (± 30 Days))
- SFA Patency: PSV Ratio > 2.4(12 Months (±30 days))
- Quality of Life Assessed (QoL) by SF-12 Questionnaire(Baseline)
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Physical Limitation(12 months (± 30 Days))
- Clinical Improvement Compared With Baseline: Rutherford Becker Scale(36 Months (± 30 Days))
- Ankle-brachial Index (ABI) on Target Limb(12 Months (± 30 Days))
- SFA Patency: PSV Ratio ≥ 2.0(6 Months (± 14 days))
- Limb Ischemia Improvement: Rutherford Becker Scale(36 Months (±30 days))
- Index Limb Amputations(36 months (±30 days))
- Quality of Life Assessed by SF-12 Questionnaire(12 Months (± 30 Days))
- Exercise Tolerance Test: Claudication Pain Time (CPT)(12 months (± 30 Days))
- Stent Fracture Rate(36 months (± 30 Days))
- Target Vessel Revascularization(36 months (±30 days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Symptoms(12 months (± 30 Days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Quality of Life(12 months (± 30 Days))
- Clinical Category: Rutherford Becker(36 Months (± 30 Days))
- Exercise Tolerance Test: Claudication Pain Distance(12 months)
- Exercise Tolerance Test: Maximal Walking Time(12 months (± 30 Days))
- Quality of Life Assessed by Peripheral Artery Questionnaire (PAQ): Summary Score(12 months (± 30 Days))
- Exercise Tolerance Test: Maximal Walking Distance(12 months (± 30 Days))
研究者
研究点 (96)
Loading locations...
相似试验
已完成
不适用
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery DiseasePeripheral Arterial DiseaseNCT03941314Kantonsspital Winterthur KSW300
撤回
不适用
Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac ArteryWith de Novo or Restenotic Lesions in the Common and/or External Iliac ArteriesNCT00613418Abbott Medical Devices
已完成
不适用
Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive CapsulitisAdhesive CapsulitisNCT06176248CHU de Reims62
已完成
不适用
Treatment of Actinic Keratosis With 5% KOH SolutionActinic KeratosesNCT04024579Infectopharm Arzneimittel GmbH73
招募中
不适用
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)Blood PressureCardiovascular DiseasesHypertensionNCT06283758Suzhou Municipal Hospital30